Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis

James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, discusses the long-term efficacy and safety results from the Phase III CHAMPION MG open-label extension (NCT03920293) of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR Ab+ gMG). Ravulizumab response was seen quite rapidly, and the agent demonstrated sustained improvements in symptoms and was well tolerated for up to 1 year in adults with AChR Ab+ gMG. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.


Research support paid to institution: Alexion Pharmaceuticals, Argenx BVBA, Cartesian Therapeutics, The Centers for Disease Control and Prevention, Millennium/Takeda Pharmaceuticals, National Institutes of Health, PCORI, Ra Pharmaceuticals (now UCB)
Honoraria: Alexion Pharmaceuticals, Argenx BVBA, Ra Pharmaceuticals (now UCB), Immunovant, Regeneron Pharmaceuticals, Sanofi US, Toleranzia AB, Viela Bio Inc (now Horizon Therapeutics)
Stock dividends: Johnson & Johnson, Pfizer, General Electric, GlaxoSmithKline